Sumatriptan 5 MG/ACTUAT Nasal Spray — RxCUI 313159
RxNorm drug concept · Semantic clinical drug
RxCUI 313159
Semantic clinical drug · SCD
● Current RxNorm concept 7 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI313159
Official nameSumatriptan 5 MG/ACTUAT Nasal Spray
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assumatriptan 5 MG/0.1 ML Nasal Spray
FDA products mapped7
Package NDCs mapped7
Reported Medicaid activity (SDUD)41,043 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Sumatriptan: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Sumatriptan stops a migraine that's already started — it does not prevent future attacks. Think of it as a rescue medicine you take when a migraine hits, not something you take eve...
- What exactly does sumatriptan do — does it prevent migraines or stop them?
- Take it as soon as you're sure a migraine attack has started. Sumatriptan works by targeting the blood vessels and nerve pathways involved in the attack, so getting it on board ear...
- When should I take it during a migraine attack?
🕸️ Concept Web — How Sumatriptan 5 MG/ACTUAT Nasal Spray Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Sumatriptan 5 MG/ACTUAT Nasal Spray
RxCUI 313159 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sumatriptan
37418IN
-
Sumatriptan
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Imitrex
217713BN
-
Imitrex
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sumatriptan Nasal Spray
379118SCDF -
Sumatriptan Inhalant Product
1163609SCDG -
Sumatriptan Nasal Product
1163611SCDG -
Sumatriptan Nasal Spray [Imitrex]
582327SBDF -
Imitrex Inhalant Product
1167768SBDG -
Imitrex Nasal Product
1167770SBDG -
Nasal Spray
126542DF -
Inhalant Product
1151123DFG - +1 more in this family
-
Sumatriptan Nasal Spray
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Sumatriptan 5 MG/ACTUAT
330250SCDC -
Sumatriptan 5 MG/ACTUAT Nasal Spray [Imitrex]
582330SBD -
Sumatriptan 5 MG/ACTUAT [Imitrex]
582329SBDC
-
Sumatriptan 5 MG/ACTUAT
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Sumatriptan 5 MG/ACTUAT
SCDC · 330250 -
Sumatriptan Nasal Spray
SCDF · 379118 -
Sumatriptan Inhalant Product
SCDG · 1163609 -
Sumatriptan Nasal Product
SCDG · 1163611
Brand-Name Concepts
-
Sumatriptan 5 MG/ACTUAT Nasal Spray [Imitrex]
SBD · 582330 -
Sumatriptan 5 MG/ACTUAT [Imitrex]
SBDC · 582329 -
Sumatriptan Nasal Spray [Imitrex]
SBDF · 582327 -
Imitrex Inhalant Product
SBDG · 1167768 -
Imitrex Nasal Product
SBDG · 1167770 -
Imitrex
BN · 217713
📦 FDA Products & Package NDCs
7 products · 7 package NDCs
7 package NDCs map to RxCUI 313159 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00527-1818-43 | 6 BLISTER PACK in 1 CARTON (0527-1818-43) / .1 mL in 1 BLIS... | Sumatriptan | Lannett Company, Inc. | 2016-02-19 |
| 00527-1859-43 | 6 BLISTER PACK in 1 CARTON (0527-1859-43) / .1 mL in 1 BLIS... | Sumatriptan | Lannett Company, Inc. | 2016-02-19 |
| 45802-0598-06 | 6 CONTAINER in 1 CARTON (45802-598-06) / 1 SPRAY in 1 CONTA... | SUMATRIPTAN | Padagis Israel Pharmaceuticals Ltd | 2020-10-04 |
| 45802-0619-06 | 6 CONTAINER in 1 CARTON (45802-619-06) / 1 SPRAY in 1 CONTA... | SUMATRIPTAN | Padagis Israel Pharmaceuticals Ltd | 2020-10-04 |
| 63629-8701-01 | 6 CONTAINER in 1 CARTON (63629-8701-1) / 1 SPRAY in 1 CONTA... | SUMATRIPTAN | Bryant Ranch Prepack | 2021-07-21 |
| 66993-0081-69 | 6 CONTAINER in 1 BOX (66993-081-69) / 100 uL in 1 CONTAINER | SUMATRIPTAN | Prasco Laboratories | 2020-07-01 |
| 66993-0082-69 | 6 CONTAINER in 1 BOX (66993-082-69) / 100 uL in 1 CONTAINER | SUMATRIPTAN | Prasco Laboratories | 2020-07-01 |
Observed labelers:
Lannett Company, Inc. (2) ·
Padagis Israel Pharmaceuticals Ltd (2) ·
Prasco Laboratories (2) ·
Bryant Ranch Prepack (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.